Search

Your search keyword '"Alcoceba, M."' showing total 19 results
Start Over Author "Alcoceba, M." Publisher wiley
19 results on '"Alcoceba, M."'

1. Molecular characterization of diffuse large‐B cell lymphoma by liquid biopsy at diagnosis and during follow‐up. OBO "Euroclonality‐NGS group" & "Grupo Colaborativo Linfomas y SLP de CyL"

Author

Alcoceba, M., primary, Stewart, J. P., additional, Álvarez, M. G., additional, Jiménez, C., additional, Medina, A., additional, Chillón, M. C., additional, Gazdova, J., additional, Blanco, Ó., additional, Díaz, L. G., additional, Villanueva, J. G., additional, Tamayo, P., additional, Esteban, C., additional, Arias, P., additional, Díaz, F. J., additional, Peñarrubia, M. J., additional, Fernández, S., additional, Cabero, A., additional, Vidriales, M. B., additional, Caballero, M. D., additional, González, M., additional, García‐Sanz, R., additional, Gutiérrez, N. C., additional, González, D., additional, García‐Sancho, A. Martín, additional, and Sarasquete, M. E., additional

Published
2023
Full Text
View/download PDF

2. Genetic and phenotypic characterization of HIV-associated aggressive B-cell non-Hodgkin lymphomas, that do not occur specifically in this population: diagnostic and prognostic implications

Author

Baptista M, Tapia G, Munoz-Marmol A, Muncunill J, Garcia O, Montoto S, Gribben J, Calaminici M, Martinez A, Veloza L, Martinez-Trillos A, Aldamiz T, Menarguez J, Terol M, Ferrandez A, Alcoceba M, Briones J, Gonzalez-Barca E, Climent F, Muntanola A, Moraleda J, Provencio M, Abrisqueta P, Abella E, Colomo L, Garcia-Ballesteros C, Garcia-Caro M, Sancho J, Ribera J, Mate J, and Navarro J

Abstract

AIMS: The frequency of aggressive subtypes of B-cell non-Hodgkin lymphoma (B-NHL), such as high-grade B-cell lymphomas (HGBL) with MYC and BCL2 and/or BCL6 rearrangement (HGBL-DH/TH) or Burkitt-like lymphoma (BL) with 11q aberration is not well known in the HIV-setting. We aimed to characterize HIV-associated aggressive B-NHL according to the 2017 WHO criteria and to identify genotypic and phenotypic features with prognostic impact. Methods and results Seventy-five HIV-associated aggressive B-NHL were studied by immunohistochemistry (CD10, BCL2, BCL6, MUM1, MYC and CD30), EBERs, and FISH to evaluate the status of the MYC, BCL2 and BCL6 genes and chromosome 11q. The 2017 WHO classification criteria and the Hans algorithm, for the cell-of-origin classification of diffuse large B-cell lymphomas (DLBCL), were applied. In DLBCL cases, the frequencies of MYC and BCL6 rearrangements (14.9 and 27.7%, respectively) were similar to those described in HIV-negative patients, but BCL2 rearrangements were infrequent (4.3%). MYC expression was identified in 23.4% of DLBCL cases, and co-expression of MYC and BCL2 in 13.0%, which was associated with a worse prognosis. As for BL cases, the expression of MUM1 (30.4%) conferred a worse prognosis. Finally, the prevalence of HGBL-DH/TH and BL-like with 11q aberration are reported in the HIV-setting.; CONCLUSIONS: The phenotypic and genotypic characteristics of HIV-associated aggressive B-NHL are similar to those of the general population, except for the low frequency of BCL2 rearrangements in DLBCL. MYC and BCL2 co-expression in DLBCL, and MUM-1 expression in BL have negative prognostic impact in HIV-infected individuals. This article is protected by copyright. All rights reserved.

Published
2022

3. OUTCOME OF 133 PATIENTS WITH FOLLICULAR LYMPHOMA (FL) PROGRESSING BEFORE 24 MONTHS (POD24) AFTER IMMUNOCHEMOTHERAPY: A GELTAMO STUDY

Author

Muntañola, A., primary, Magnano, L., additional, Mercadal, S., additional, Huguet, M., additional, Bobillo, S., additional, Bastos‐Oreiro, M., additional, Jiménez‐Ubieto, A., additional, Rovira, J., additional, Rivero, A., additional, Alcoceba, M., additional, Mozas, P., additional, Luizaga, L., additional, Alonso‐Álvarez, S., additional, Rivas‐Delgado, A., additional, Giné, E., additional, Caballero, D., additional, Sancho, J. M., additional, and López‐Guillermo, A., additional

Published
2021
Full Text
View/download PDF

4. TESTICULAR DIFFUSE LARGE B‐CELL LYMPHOMA: CLINICO‐BIOLOGICAL CHARACTERIZATION, EVALUATION OF TREATMENT RESPONSE AND SURVIVAL

Author

Rivas‐Delgado, A., primary, López, C., additional, Nadeu, F., additional, Grau, M., additional, Rivero, A., additional, Bosch, J., additional, Alcoceba, M., additional, Gustavo, T., additional, Luizaga, L., additional, Barcena, C., additional, Kelleher, N., additional, Martin, S., additional, Mozas, P., additional, Balague, O., additional, Frigola, G., additional, Magnano, L., additional, Baumann, T., additional, Villamor, N., additional, Muntañola, A., additional, Sancho, J. M., additional, García‐Sancho, A. Martin, additional, Gonzalez‐Barca, E., additional, Climent, F., additional, Campo, E., additional, Giné, E., additional, López‐Guillermo, A., additional, and Beà, S., additional

Published
2021
Full Text
View/download PDF

5. Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population

Author

Magnano L, Alonso-Alvarez S, Alcoceba M, Rivas-Delgado A, Muntanola A, Nadeu F, Setoain X, Rodriguez S, Andrade-Campos M, Espinosa-Lara N, Rodriguez G, Sancho J, Moreno M, Mercadal S, Carro I, Salar A, Garcia-Pallarols F, Arranz R, Cannata J, Terol M, Teruel A, Jimenez-Ubiet A, Rodrigue A, de Villambrosi S, Bell J, Lopez L, Novelli S, de Cabo E, Infante M, Pardal E, Monsalvo S, Gonzalez M, Martin A, Caballero M, Lopez-Guillermo A, and GELTAMO

Published
2019

6. CAR T-CELLS ARE ARRIVING. IS ALLOGENEIC TRANSPLANT AN OBSOLETE APPROACH FOR DE NOVO/TRANSFORMED DLBCL IN THE CAR T-CELLS ERA? LONG-TERM FOLLOW-UP OF A SINGLE CENTRE UNIT

Author

Prieto-García, L., primary, Alcoceba, M., additional, Pérez-López, E., additional, López-Corral, L., additional, Delgado, M., additional, Sánchez-Guijo, F., additional, Martín, A., additional, Navarro-Bailón, A., additional, Baile, M., additional, López-Parra, M., additional, Tamayo, P., additional, Gutiérrez, N.C., additional, Vázquez, L., additional, Cabrero, M., additional, and Caballero, D., additional

Published
2019
Full Text
View/download PDF

7. EVALUATION OF BONE MARROW INFILTRATION BY MULTIDIMENSIONAL FLOW CYTOMETRY IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA: SUB-STUDY OF A PHASE 2 GELTAMO CLINICAL TRIAL

Author

Baile, M., primary, Barrena, S., additional, Sancho, J., additional, Grande, C., additional, Fernández, R., additional, Batlle, A., additional, Peñarrubia, M., additional, Peñalver, F., additional, Hernández-Rivas, J., additional, Guinea, M., additional, Pérez, J., additional, García-Álvarez, M., additional, Alcoceba, M., additional, Vidriales, B., additional, Orfao, A., additional, and Martín, A., additional

Published
2019
Full Text
View/download PDF

8. Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array

Author

García-Sanz R, Corchete LA, Alcoceba M, Chillon MC, Jiménez C, Prieto I, García-Álvarez M, Puig N, Rapado I, Barrio S, Oriol A, Blanchard MJ, de la Rubia J, Martínez R, Lahuerta JJ, González Díaz M, Mateos MV, San Miguel JF, Martínez-López J, Sarasquete ME, and GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en

Subjects
bortezomib-induced peripheral neuropathy, genome-wide association studies, multiple myeloma, thalidomide-induced peripheral neuropathy
Abstract

Bortezomib- and thalidomide-based therapies have significantly contributed to improved survival of multiple myeloma (MM) patients. However, treatment-induced peripheral neuropathy (TiPN) is a common adverse event associated with them. Risk factors for TiPN in MM patients include advanced age, prior neuropathy, and other drugs, but there are conflicting results about the role of genetics in predicting the risk of TiPN. Thus, we carried out a genome-wide association study based on more than 300 000 exome single nucleotide polymorphisms in 172 MM patients receiving therapy involving bortezomib and thalidomide. We compared patients developing and not developing TiPN under similar treatment conditions (GEM05MAS65, NCT00443235). The highest-ranking single nucleotide polymorphism was rs45443101, located in the PLCG2 gene, but no significant differences were found after multiple comparison correction (adjusted P = .1708). Prediction analyses, cytoband enrichment, and pathway analyses were also performed, but none yielded any significant findings. A copy number approach was also explored, but this gave no significant results either. In summary, our study did not find a consistent genetic component associated with TiPN under bortezomib and thalidomide therapies that could be used for prediction, which makes clinical judgment essential in the practical management of MM treatment.

Published
2017

9. Whole-exome analysis of abnormalities leading to Waldenström's macroglobulinemia transformation into aggressive lymphoma

Author

Alcoceba, M., primary, Jiménez, C., additional, Alonso-Álvarez, S., additional, Ordóñez, G.R., additional, García-Álvarez, M., additional, Prieto-Conde, M.I., additional, Chillón, M.C., additional, Balanzategui, A., additional, Corral, R., additional, Marín, L.A., additional, Gutiérrez, N.C., additional, Puig, N., additional, Sarasquete, M.E., additional, González, M., additional, and García-Sanz, R., additional

Published
2017
Full Text
View/download PDF

10. PATIENTS WITH FOLLICULAR LYMPHOMA (FL) IN MAINTAINED COMPLETE RESPONSE (CR) AT 30 MONTHS SHOW A SURVIVAL SIMILAR TO A SEX- AND AGE-MATCHED SPANISH GENERAL POPULATION

Author

Magnano, L., primary, Alonso-Alvarez, S., additional, Alcoceba, M., additional, Rivas-Delgado, A., additional, Muntañola, A., additional, Andrade-Campos, M., additional, Rodriguez, G., additional, Sancho, J., additional, Mercadal, S., additional, Salar, A., additional, Arranz, R., additional, Terol, M., additional, Jiménez-Ubieto, A., additional, González de Villambrosía, S., additional, Bello, J., additional, López, L., additional, Novelli, S., additional, De Cabo, E., additional, Infante, M., additional, Pardal, E., additional, Canals, M., additional, González, M., additional, Martín, A., additional, Caballero, M., additional, and López-Guillermo, A., additional

Published
2017
Full Text
View/download PDF

11. CLINICAL CHARACTERISTICS AND PROGNOSIS OF ELDERLY (>70 YEARS) FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA: MULTICENTRE RETROSPECTIVE ANALYSIS OF THE GELTAMO SPANISH GROUP

Author

Alcoceba, M., primary, Magnano, L., additional, Alonso-Álvarez, S., additional, Andrade-Campos, M., additional, Espinosa-Lara, N., additional, Rodríguez, G., additional, Sancho, J.M., additional, Moreno, M., additional, Mercadal, S., additional, García-Pallarols, F., additional, Cannata, J., additional, Teruel, A.I., additional, Rodríguez, A., additional, González de Villambrosía, S., additional, Bello, J., additional, López, L.I., additional, Monsalvo, S., additional, Novelli, S., additional, de Cabo, E., additional, Infante, M.S., additional, Pardal, E., additional, Muntañola, A., additional, González, M., additional, Caballero, M.D., additional, Martín, A., additional, and López-Guillermo, A., additional

Published
2017
Full Text
View/download PDF

12. APPLICATION OF CELL-OF-ORIGIN SUBTYPES DETERMINED BY DIGITAL GENE EXPRESSION IN HIV-RELATED DIFFUSE LARGE B-CELL LYMPHOMAS

Author

Baptista, M., primary, Tapia, G., additional, Muñoz-Marmol, A., additional, Muncunill, J., additional, Montoto, S., additional, Gribben, J., additional, Calaminici, M., additional, Martinez, A., additional, Gonzalez-Farre, B., additional, López-Guillermo, A., additional, González-Barca, E., additional, Terol, M., additional, Miralles, P., additional, Alcoceba, M., additional, Vall-Llovera, F., additional, Briones, J., additional, Abrisqueta, P., additional, Abella, E., additional, Provencio, M., additional, García-Ballesteros, C., additional, Moraleda, J., additional, Sancho, J., additional, Ribera, J., additional, Mate, J., additional, and Navarro, J., additional

Published
2017
Full Text
View/download PDF

13. THE RISK OF TRANSFORMATION OF FOLLICULAR LYMPHOMA “TRANSFORMED” BY RITUXIMAB: THE ARISTOTLE STUDY PROMOTED BY THE EUROPEAN LYMPHOMA INSTITUTE

Author

Federico, M., primary, Caballero, D., additional, Marcheselli, L., additional, Tarantino, V., additional, Sarkozy, C., additional, Lopez Guillermo, A., additional, Wondergem, M., additional, Kimby, E., additional, Rusconi, C., additional, Zucca, E., additional, Montoto, S., additional, da Silva, M.G., additional, Aurer, I., additional, Paszkiewicz-Kozik, E., additional, Cartron, G., additional, Morschhauser, F., additional, Alcoceba, M., additional, Chamuleau, M., additional, Lockmer, S., additional, Minoia, C., additional, Issa, D., additional, Alonso, S., additional, Conte, L., additional, Salles, G., additional, and Coiffier, B., additional

Published
2017
Full Text
View/download PDF

14. GENE MUTATIONS AND COPY NUMBER ALTERATIONS (CNA) PREDICT FOR EARLY FAILURE IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) TREATED WITH R-CHOP

Author

Dlouhy, I., primary, Karube, K., additional, Enjuanes, A., additional, Salaverría, I., additional, Pérez-Galán, P., additional, Jares, P., additional, Martín-García, D., additional, Nadeu, F., additional, Rivas-Delgado, A., additional, Rovira, J., additional, Gonzalez, B., additional, Mozos, A., additional, Clot, G., additional, Sancho, J.M., additional, Salar, A., additional, Mercadal, S., additional, Escola, L., additional, Briones, J., additional, Colomo, L., additional, Alcoceba, M., additional, Valera, A., additional, Campo, E., additional, and López-Guillermo, A., additional

Published
2017
Full Text
View/download PDF

15. Post-transplant monomorphic Burkitt's lymphoma: Clinical characteristics and outcome of a multicenter series

Author

Bobillo, S., primary, Abrisqueta, P., additional, Sánchez-González, B., additional, Giné, E., additional, Romero, S., additional, Alcoceba, M., additional, González-Barca, E., additional, González de Villambrosía, S., additional, Sancho, J.M., additional, Castellví, J., additional, López, A., additional, and Bosch, F., additional

Published
2017
Full Text
View/download PDF

16. CXCR4 expression enhances diffuse large B cell lymphoma dissemination and decreases patient survival

Author

Mj, Moreno, Bosch R, Dieguez-Gonzalez R, Silvana Novelli, Mozos A, Gallardo A, Ma, Pavón, Mv, Céspedes, Grañena A, Alcoceba M, Blanco O, Gonzalez-Díaz M, Sierra J, Mangues R, and Casanova I

Subjects
cancer patient, Ge, cell migration, rituximab, cell motion, Cell Movement, middle aged, animal, genetics, cancer survival, pathophysiology, large cell lymphoma, progression free survival, tumor biopsy, disease course, gene expression regulation, tumor engraftment, female, priority journal, Disease Progression, survival rate, in vitro study, overall survival, animal experiment, cancer prognosis, CXCR4 protein, human, Article, animal tissue, in vivo study, male, Cell Line, Tumor, stromal cell derived factor 1alpha, SCID mouse, Animals, controlled study, human, drug screening, survival time, protein expression, mouse, antagonists and inhibitors, heterocyclic compound, nonhuman, chemokine receptor CXCR4, animal model, human cell, disease model, nonobese diabetic mouse, plerixafor, tumor cell line, tumor invasion, mortality, human tissue, tumor xenograft, Disease Models, Animal, drug effects, physiology, pathology, prognosis
Abstract

The chemokine receptor CXCR4 has been implicated in the migration and trafficking of malignant B cells in several haematological malignancies. Over-expression of CXCR4 has been identified in haematological tumours, but data concerning the role of this receptor in diffuse large B cell lymphoma (DLBCL) are lacking. CXCR4 is a marker of poor prognosis in various neoplasms, correlating with metastatic disease and decreased survival of patients. We studied CXCR4 involvement in cell migration in vitro and dissemination in vivo. We also evaluated the prognostic significance of CXCR4 in 94 biopsies of DLBCL patients. We observed that the level of expression of CXCR4 in DLBCL cell lines correlated positively with in vitro migration. Expression of the receptor was also associated with increased engraftment and dissemination, and decreased survival time in NOD/SCID mice. Furthermore, administration of a specific CXCR4 antagonist, AMD3100, decreased dissemination of DLBCL cells in a xenograft mouse model. In addition, we found that CXCR4 expression is an independent prognostic factor for shorter overall survival and progression-free survival in DLBCL patients. These results show that CXCR4 mediates dissemination of DLBCL cells and define for the first time its value as an independent prognostic marker in DLBCL patients. © 2014 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Published
2015

17. Frequency of HLA-A, -B and -DRB1 specificities and haplotypic associations in the population of Castilla y León (northwest-central Spain)

Author

Alcoceba, M., primary, Marín, L., additional, Balanzategui, A., additional, Sarasquete, M. E., additional, Chillón, M. C., additional, Martín-Jiménez, P., additional, Puig, N., additional, Santamaría, C., additional, Corral, R., additional, García-Sanz, R., additional, San Miguel, J. F., additional, and González, M., additional

Published
2011
Full Text
View/download PDF

18. The presence of DRB1*01 allele in multiple myeloma patients is associated with an indolent disease

Author

Alcoceba, M., primary, Marín, L., additional, Balanzategui, A., additional, Sarasquete, M. E., additional, Martín‐Jiménez, P., additional, Chillón, M. C., additional, Corral, R., additional, Pérez‐Persona, E., additional, Fernández‐Calvo, F. J., additional, Hernández, J. M., additional, Bladé, J., additional, Lahuerta, J. J., additional, González, M., additional, San Miguel, J. F., additional, and García‐Sanz, R., additional

Published
2008
Full Text
View/download PDF

19. Low expression of ZHX2, but not RCBTB2 or RAN, is associated with poor outcome in multiple myeloma

Author

Armellini, A., primary, Sarasquete, M. E., additional, García‐Sanz, R., additional, Chillón, M. C., additional, Balanzategui, A., additional, Alcoceba, M., additional, Fuertes, M., additional, López, R., additional, Hernández, J. M., additional, Fernández‐Calvo, J., additional, Sierra, M., additional, Megido, M., additional, Orfão, A., additional, Gutiérrez, N. C., additional, González, M., additional, and San Miguel, J. F., additional

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results